Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 259

Similar articles for PubMed (Select 16428469)


Erythropoietin biology in cancer.

Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW.

Clin Cancer Res. 2006 Jan 15;12(2):332-9. Review.


Erythropoietin and erythropoietin receptor in hepatocellular carcinoma: correlation with vasculogenic mimicry and poor prognosis.

Yang Z, Sun B, Zhao X, Shao B, An J, Gu Q, Wang Y, Dong X, Zhang Y, Qiu Z.

Int J Clin Exp Pathol. 2015 Apr 1;8(4):4033-43. eCollection 2015.


Poly-γ-glutamic acid enhances the quality of recombant erythropoietin produced by CHO cells.

Kim TG, Cho YC, Chun BH, Park SH, Lee HS, Chung N.

Biotechnol Biotechnol Equip. 2014 Mar 4;28(2):350-354.


Erythropoietin improves the accumulation and therapeutic effects of Carboplatin by enhancing tumor vascularization and perfusion.

Doleschel D, Rix A, Arns S, Palmowski K, Gremse F, Merkle R, Salopiata F, Klingmüller U, Jarsch M, Kiessling F, Lederle W.

Theranostics. 2015 May 1;5(8):905-18. doi: 10.7150/thno.11304. eCollection 2015.


Erythropoietin Receptor Antagonist Suppressed Ectopic Hemoglobin Synthesis in Xenografts of HeLa Cells to Promote Their Destruction.

Yasuda Y, Fujita M, Koike E, Obata K, Shiota M, Kotani Y, Musha T, Tsuji-Kawahara S, Satou T, Masuda S, Okano J, Yamasaki H, Okumoto K, Uesugi T, Nakao S, Hoshiai H, Mandai M.

PLoS One. 2015 Apr 15;10(4):e0122458. doi: 10.1371/journal.pone.0122458. eCollection 2015.


Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.

Collino M, Thiemermann C, Cerami A, Brines M.

Pharmacol Ther. 2015 Jul;151:32-40. doi: 10.1016/j.pharmthera.2015.02.005. Epub 2015 Feb 26. Review.


Cardiac remodeling in response to chronic iron deficiency: role of the erythropoietin receptor.

Naito Y, Sawada H, Oboshi M, Iwasaku T, Okuhara Y, Morisawa D, Eguchi A, Hirotani S, Mano T, Tsujino T, Masuyama T.

J Hypertens. 2015 Jun;33(6):1267-75. doi: 10.1097/HJH.0000000000000547.


Discovery of a master regulator of injury and healing: tipping the outcome from damage toward repair.

Brines M.

Mol Med. 2014 Dec 16;20 Suppl 1:S10-6. doi: 10.2119/molmed.2014.00167.


Erythropoietin and cancer: the unintended consequences of anemia correction.

Debeljak N, Solár P, Sytkowski AJ.

Front Immunol. 2014 Nov 11;5:563. doi: 10.3389/fimmu.2014.00563. eCollection 2014. Review.


Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system.

Wang L, Di L, Noguchi CT.

Int J Biol Sci. 2014 Aug 23;10(8):921-39. doi: 10.7150/ijbs.9518. eCollection 2014. Review.


EPO promotes bone repair through enhanced cartilaginous callus formation and angiogenesis.

Wan L, Zhang F, He Q, Tsang WP, Lu L, Li Q, Wu Z, Qiu G, Zhou G, Wan C.

PLoS One. 2014 Jul 8;9(7):e102010. doi: 10.1371/journal.pone.0102010. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e111830.


[Progress on neuroprotective effects of erythropoietin].

Liu X, Wu H.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013 Nov;42(6):693-9. Review. Chinese.


Erythropoietin and the heart: physiological effects and the therapeutic perspective.

Sanchis-Gomar F, Garcia-Gimenez JL, Pareja-Galeano H, Romagnoli M, Perez-Quilis C, Lippi G.

Int J Cardiol. 2014 Feb 1;171(2):116-25. doi: 10.1016/j.ijcard.2013.12.011. Epub 2013 Dec 18. Review.


The role of erythropoietin and erythropoietin receptor in malignant laryngeal tumors.

Vukelic J, Dobrila-Dintinjana R, Jonjic N, Dekanic A, Ilijic V.

Med Hypotheses. 2013 Dec;81(6):1155-8. doi: 10.1016/j.mehy.2013.09.030. Epub 2013 Oct 1.


Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells.

Liang K, Qiu S, Lu Y, Fan Z.

Cancer Biol Ther. 2014 Jan;15(1):89-98. doi: 10.4161/cbt.26717. Epub 2013 Oct 22.


Erythropoietin use in CKD patients with cancer: to tread with caution?

Nayak-Rao S, McCormick B.

J Nephrol. 2013 Sep-Oct;26(5):829-35. doi: 10.5301/jn.5000316. Epub 2013 Sep 18. Review.


Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions.

Miyake M, Goodison S, Lawton A, Zhang G, Gomes-Giacoia E, Rosser CJ.

J Hematol Oncol. 2013 Sep 3;6:65. doi: 10.1186/1756-8722-6-65.


The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection.

Bartnicki P, Kowalczyk M, Rysz J.

Med Sci Monit. 2013 Jul 22;19:599-605. doi: 10.12659/MSM.889023. Review.


Erythropoietin receptor (EpoR) agonism is used to treat a wide range of disease.

Sanchis-Gomar F, Perez-Quilis C, Lippi G.

Mol Med. 2013 Apr 30;19:62-4. doi: 10.2119/molmed.2013.00025.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk